U.S. Markets open in 14 mins
  • S&P Futures

    4,407.25
    -7.00 (-0.16%)
     
  • Dow Futures

    34,947.00
    -87.00 (-0.25%)
     
  • Nasdaq Futures

    15,117.75
    0.00 (0.00%)
     
  • Russell 2000 Futures

    2,200.30
    -13.10 (-0.59%)
     
  • Crude Oil

    71.87
    -0.04 (-0.06%)
     
  • Gold

    1,802.10
    +2.90 (+0.16%)
     
  • Silver

    25.15
    -0.17 (-0.68%)
     
  • EUR/USD

    1.1825
    +0.0017 (+0.1419%)
     
  • 10-Yr Bond

    1.2480
    -0.0280 (-2.19%)
     
  • Vix

    18.57
    +1.37 (+7.97%)
     
  • GBP/USD

    1.3823
    -0.0001 (-0.0069%)
     
  • USD/JPY

    109.8790
    -0.4960 (-0.4494%)
     
  • BTC-USD

    38,307.07
    +334.26 (+0.88%)
     
  • CMC Crypto 200

    912.01
    -3.48 (-0.38%)
     
  • FTSE 100

    6,997.56
    -27.87 (-0.40%)
     
  • Nikkei 225

    27,970.22
    +136.93 (+0.49%)
     

Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network

·1 min read

A photo is available on Business Wire's website and the Associated Press Photo Network of Biohaven Pharmaceuticals (NYSE: BHVN) ringing the opening bell, June 8, 2021. BJ Jones, Chief Commercial Officer, Migraine & Common Disease and Vlad Coric, M.D., Chief Executive Officer of Biohaven ring the opening bell at the New York Stock Exchange in support of the migraine community and Migraine and Headache Awareness Month and to celebrate the FDA approval of the first and only medicine to treat and prevent migraine.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005948/en/

BJ Jones, Chief Commercial Officer, Migraine & Common Disease and Vlad Coric, M.D., Chief Executive Officer of Biohaven ring the opening bell at the New York Stock Exchange in support of the migraine community and Migraine and Headache Awareness Month and to celebrate the FDA approval of the first and only medicine to treat and prevent migraine. (Photo: NYSE)

View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005948/en/

Contacts

Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com